IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.708
NA - Nord America 3.134
AS - Asia 1.807
SA - Sud America 544
Continente sconosciuto - Info sul continente non disponibili 217
AF - Africa 59
OC - Oceania 3
Totale 9.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.054
RU - Federazione Russa 1.812
SG - Singapore 758
BR - Brasile 469
CN - Cina 454
IE - Irlanda 427
IT - Italia 382
SE - Svezia 355
PL - Polonia 218
HK - Hong Kong 175
DE - Germania 124
FR - Francia 114
VN - Vietnam 112
IN - India 66
HU - Ungheria 61
GB - Regno Unito 51
BD - Bangladesh 40
FI - Finlandia 37
CA - Canada 29
ID - Indonesia 29
MX - Messico 28
AR - Argentina 23
BE - Belgio 22
IQ - Iraq 21
JP - Giappone 21
TR - Turchia 20
AT - Austria 19
NL - Olanda 19
PK - Pakistan 17
ZA - Sudafrica 17
UA - Ucraina 14
ES - Italia 13
EG - Egitto 12
MA - Marocco 12
PH - Filippine 12
LT - Lituania 10
VE - Venezuela 10
CO - Colombia 9
AZ - Azerbaigian 8
EC - Ecuador 8
KR - Corea 8
MY - Malesia 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
BO - Bolivia 6
CL - Cile 6
CZ - Repubblica Ceca 6
TW - Taiwan 6
CR - Costa Rica 5
JO - Giordania 5
KE - Kenya 5
NI - Nicaragua 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
TN - Tunisia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
KG - Kirghizistan 3
NP - Nepal 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EU - Europa 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LY - Libia 2
MN - Mongolia 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AO - Angola 1
BG - Bulgaria 1
BM - Bermuda 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
Totale 9.252
Salva come PNG Salva come JPEG
Città #
Ashburn 603
Moscow 528
Singapore 441
Dublin 427
Chandler 384
Dallas 344
Nyköping 228
Warsaw 212
Hong Kong 174
Messina 165
Beijing 144
San Jose 141
The Dalles 87
Council Bluffs 78
Los Angeles 78
Princeton 76
Medford 64
Ann Arbor 63
Budapest 59
Lauterbourg 59
New York 52
Munich 50
Des Moines 47
Jacksonville 43
Dearborn 41
Santa Clara 39
São Paulo 39
Frankfurt am Main 32
Buffalo 30
Ho Chi Minh City 29
Dong Ket 25
Hanoi 23
Tianjin 23
Brussels 22
Milan 21
Redondo Beach 21
Rio de Janeiro 21
Boardman 18
Brooklyn 18
Cambridge 18
Chennai 18
Nuremberg 18
Rome 18
Tokyo 18
Wilmington 18
Jakarta 17
Belo Horizonte 16
Jinan 16
Turku 16
Woodbridge 16
Chicago 14
Nanjing 14
Orem 14
Houston 13
Denver 12
Hangzhou 12
Montreal 12
Pune 12
Vienna 12
Bremen 11
Guangzhou 11
Hebei 10
Johannesburg 10
Cairo 9
London 8
Ningbo 8
Palermo 8
Paris 8
Porto Alegre 8
San Francisco 8
San Mateo 8
Seattle 8
Shanghai 8
Zhengzhou 8
Baku 7
Boston 7
Brasília 7
Lahore 7
Shenyang 7
Atlanta 6
Helsinki 6
Hillsboro 6
Istanbul 6
Manchester 6
Mexico City 6
Osasco 6
Poplar 6
Redwood City 6
Stockholm 6
Tashkent 6
Toronto 6
Amman 5
Baghdad 5
Belém 5
Bengaluru 5
Casablanca 5
Columbus 5
Curitiba 5
Fortaleza 5
Fuzhou 5
Totale 5.536
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 300
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 257
A multivariate analysis of Multiple Myeloma subtype plasma cells 251
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 244
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 237
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 217
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 204
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 201
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 195
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 193
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 193
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 189
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 185
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 182
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 181
Vaccination of multiple myeloma: Current strategies and future prospects 175
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 174
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 173
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 172
Telomerase and telomere biology in hematological diseases: A new therapeutic target 169
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 169
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 167
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules 164
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 160
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 158
Vaccination strategies in lymphoproliferative disorders: Failures and successes 155
The cancer stem cell hypothesis: a guide to potential molecular targets. 154
Standardisation of minimal residual disease in multiple myeloma 153
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 151
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 148
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 147
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 144
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 142
The metabolomic signature of hematologic malignancies 139
Role of the microbiota in hematologic malignancies. 139
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 137
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 133
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 125
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 122
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 117
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 117
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 115
Nanobodies and Cancer: Current Status and New Perspectives 114
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 112
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 110
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 105
Immune thrombocytopenia: options and new perspectives 104
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 99
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 98
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 98
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 96
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 94
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 92
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 91
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 90
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 86
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 84
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 83
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 80
New orally active proteasome inhibitors in multiple myeloma. 78
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 78
Relationship between mitofusin 2 and cancer. 76
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 74
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 74
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 67
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 67
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 55
null 19
Totale 9.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022482 0 25 8 22 14 11 27 19 22 96 39 199
2022/20231.278 119 135 65 120 65 123 9 70 505 11 35 21
2023/2024335 22 75 28 26 29 62 2 20 1 17 7 46
2024/20251.557 83 32 21 89 91 73 36 243 402 96 173 218
2025/20264.586 231 284 373 249 409 874 624 582 594 216 57 93
2026/2027207 104 103 0 0 0 0 0 0 0 0 0 0
Totale 9.472